leadership  aduro biotech pioneering immunotherapy transforming lives leadership stephen t isaacs chairman president and ceo thomas w dubensky jr phd chief scientific officer natalie r sacks md chief medical officer gregory w schafer chief operating officer hans van eenennaam phd chief operational officer aduro biotech europe andrea van elsas phd chief scientific officer aduro biotech europe   dirk g brockstedt phd executive vice president research  development jennifer lew senior vice president finance quoc lenguyen senior vice president chemistry manufacturing and control blaine templeman executive vice president general counsel and secretary sylvia wheeler senior vice president corporate affairs and investor relations   michele devries vice president regulatory affairs celeste ferber vice president associate general counsel nancy kaplan vice president human resources and facility operations anne moon phd vice president project management aimee murphy vice president clinical development and operations justin skoble phd vice president technical operations liana wu vice president commercial stephen t isaacs chairman president and ceo stephen t isaacs has served as our chairman president and chief executive officer since  prior to aduro in  mr isaacs founded cerus corporation a biomedical products company that commercialized the intercept blood systems he served as president and chief executive officer of cerus from  to  prior to cerus mr isaacs founded and served as chief executive officer and president of hri associates and hri research both biotechnology companies focused on research and development he held a nonteaching faculty position in the department of chemistry at the university of california berkeley from  to  mr isaacs has published over  peerreviewed scientific articles and is an inventor on over  issued patents mr isaacs holds a ba degree in biochemistry from university of california berkeley and had graduate training in organic chemistry in the phd program in the department of chemistry at berkeley  thomas w dubensky jr phd chief scientific officer thomas w dubensky jr phd has served as our chief scientific officer since september  from  to  dr dubensky served as chief scientific officer of immune design where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms prior to this in  he cofounded and served as chief scientific officer of anza therapeutics a biotechnology company that was spun out from cerus corporation where he had served as vice president of research for the five years prior  during this time dr dubensky helped to develop vaccine platforms based on attenuated strains of listeria monocytogenes which serves as the technology basis for aduro’s ladd platform earlier in his career dr dubensky developed vaccine platforms based on alphaviruses adenoviruses retroviruseslentiviruses and plasmid dna at a number of biotechnology companies including viagene chiron corporation and onyx pharmaceuticals dr dubensky has coauthored more than  scientific papers and is an inventor on  issued us patents with multiple pending applications dr dubensky received his ba in bacteriology and immunology from the university of california berkeley and his phd at the university of colorado health sciences center  he conducted his postdoctoral fellowship at harvard medical school in the department of pathology natalie r sacks md chief medical officer natalie sacks md has served as our chief medical officer since september  prior to joining aduro dr sacks served as an advisor on development strategy for multiple firms previously she was vice president of clinical development at onyx pharmaceuticals acquired by amgen where she played a key role in the development and approval of kyprolis® an fdaapproved therapy for the treatment of relapsed or refractory multiple myeloma and in business development strategy prior to that she served as vice president of clinical research for exelixis where she directed the development of a portfolio of small molecules with responsibilities ranging from ind filings to latestage development including latestage development of cometriq™ an fdaapproved therapy for the treatment of medullary thyroid cancer earlier in her career dr sacks served as vice president of clinical development at cell genesys a company focused on the development of cancer vaccines and engineered chimeric antigen receptor car t cells prior to her tenure in biotechnology she served in a variety of research and analytical roles at academic institutions and companies including massachusetts general hospital medical college of pennsylvania and icistuart pharmaceuticals in addition to her industry experience dr sacks holds an active faculty appointment at the university of california san francisco where she is an assistant clinical professor of medicine in the division of hematologyoncology she received her md from the university of pennsylvania school of medicine her ms in biostatistics from harvard university school of public health and her ba in mathematics from bryn mawr college gregory w schafer chief operating officer gregory w schafer has served as our chief operating officer since july  prior to joining aduro he served as chief financial officer of jennerex biotherapeutics acquired by sillajen a privately held biotechnology company from june  to july  where he was responsible for finance accounting planning investor relations and treasury functions from april  to january  he served as chief financial officer of onyx pharmaceuticals acquired by amgen where he was responsible for finance accounting risk management and strategic and operational planning earlier in his career mr schafer served as chief financial officer and vice president of finance for intrabiotics pharmaceuticals and cerus corporation prior to entering the field of biotechology he worked as a management consultant for deloitte  touche llp he received his mba from the anderson graduate school of management at the university of california los angeles and a bse in mechanical engineering from the university of pennsylvania hans van eenennaam phd chief operational officer aduro biotech europe hans van eenennaam phd became chief operational officer of aduro biotech europe in november  prior to its acquisition by aduro in  dr van eenennaam served as chief operational officer of bionovion a company he cofounded in  to focus on the development of innovative therapeutic antibodies in the field of immune oncology  earlier in his career he held numerous positions of increasing responsibility at organon in oss netherlands and the organon research center in cambridge massachusetts which was acquired by scheringplough corporation in  and later by merck  co he led the discovery and development of therapeutic monoclonal antibodies and small molecule entities in the field of oncology and immunology  while at organon dr van eenennaam in cooperation with a team of scientists discovered pembrolizumab keytruda® a humanized therapeutic antibody acquired by merck and approved in  by the us food and drug administration for the treatment of melanoma and subsequently for additional indications including nonsmall cell lung cancer and head and neck cancer  in  he and colleagues were honored by the intellectual property owner’s association with the rd annual inventor of the year award he is named as inventor on seven pending and granted patent families including the patents claiming keytruda and author on over  publications  dr van eenennaam received his doctorate in autoimmune biochemistry cum laude from radboud university in nijmegen netherlands dr andrea van elsas phd chief scientific officer aduro biotech europe andrea van elsas became chief scientific officer of aduro biotech europe in november   prior to its acquisition by aduro in  dr andrea van elsas cofounded bionovion and served as chief scientific officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology  from  to  he held numerous positions at organon in oss netherlands and cambridge massachusetts acquired by scheringplough corporation in  and later by merck  co and as the director of tumor immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab as a postdoctoral researcher from  andrea worked at the university of california berkeley studying antibodies blocking ctla for the treatment of cancer and is a coinventor on the original patents that formed the basis for the development of yervoy® ipilimumab the first checkpoint inhibitor approved in  by the us food and drug administration for the treatment of melanoma   dirk g brockstedt phd executive vice president research  development dirk g brockstedt phd joined aduro in april  and has served as our senior vice president of research and development since september  prior to joining aduro dr brockstedt held various positions of increasing responsibility in the immunotherapy group at cerus corporation culminating as director of immunology  earlier in his career dr brockstedt worked as a scientist at aventis in the immunotherapy and antiangiogenesis group from  until  focused on developing novel anticancer therapies he has coauthored  scientific papers and is a named inventor on five issued patents and several pending applications dr brockstedt holds a diplomamasters of science in microbiology from the university of kiel and earned his phd from the university of kiel and stanford university the latter at which he served as a postdoctoral fellow at the stanford school of medicine in the department of pathology jennifer lew senior vice president finance jennifer lew joined aduro in october  and has served as our senior vice president of finance since january  prior to joining aduro from  to  ms lew held various positions of increasing responsibility at dynavax technologies culminating as vice president of finance and principal accounting officer responsible for all accounting and finance operations earlier in her career ms lew served as assistant controller and director of finance at qrs corporation a publiclyheld technology company and was a member of the audit practice at ernst  young ms lew earned a ba in economicsaccounting and government from claremont mckenna college and is a certified public accountant inactive status quoc lenguyen senior vice president chemistry manufacturing and control quoc lenguyen joined aduro in september  and has served as our senior vice president of chemistry manufacturing and control cmc since september  he brings over  years of experience in biopharmaceutical operations having held positions of increasing responsibility at both large pharmaceutical and startup companies prior to joining aduro mr lenguyen spent seven years at bayer healthcare as the vice president of technical operations before bayer he served at chiron corporation and novartis ag as director of manufacturing operations earlier in his career he served as senior manager of manufacturing operations at biomarin pharmaceutical where he played an integral role in bringing the company’s lead drug candidate from phase  to commercial launch mr lenguyen holds a bs from university of california davis in biochemistry blaine templeman executive vice president general counsel and secretary blaine templeman joined aduro as executive vice president general counsel and secretary in september  he brings over  years of experience counseling biotechnology companies in the development and commercialization of their products prior to joining aduro mr templeman was a corporate and intellectual property partner at arnold  porter llp where he counseled us and international clients on the protection development and commercialization of their products intellectual property portfolios contract manufacturing clinical trials research and outsourcing his transactional experience includes a variety of collaborations licensing transactions mergers and acquisitions asset sales manufacturing and distribution arrangements and copromotion transactions before arnold  porter llp he was a partner at heller ehrman mr templeman holds a jd from new york university and a bs from oral roberts university sylvia wheeler senior vice president corporate affairs and investor relations sylvia wheeler joined aduro as senior vice president corporate affairs and investor relations in january  she brings over  years of experience in the biopharmaceutical industry having served in a number of executive management roles encompassing investor and media relations as well as corporate and product communications prior to joining aduro ms wheeler served as vice president of investor relations and corporate affairs at relypsa after having served this same role for hyperion therapeutics earlier in her career she was vice president corporate communications at affymax where over a sixyearperiod she supported the company’s transition from a research and development company to a commercial organization with its first marketed product ms wheeler held similar communications roles at depomed cerus corporation and coulter pharmaceutical ms wheeler holds an mba from university of san francisco and a ba in biology from san francisco state university michele devries vice president regulatory affairs michele devries joined aduro in  and currently serves as vice president of regulatory affairs  she is responsible for all aspects of regulatory strategy implementation and oversight of aduro’s proprietary partnered and licensed programs both in the us and internationally prior to aduro ms devries served as director of regulatory affairs for intarcia therapeutics  in this role she managed key regulatory aspects of intarcia’s drug delivery system served as the primary contact for regulatory authorities and was responsible for all aspects of routine and specialized regulatory submissions including preparation for launch of four global phase  studies before intarcia she held escalating regulatory affairs positions at vaxgen intermune and tularik  she received her bs in chemical engineering from the university of minnesota celeste ferber vice president associate general counsel celeste ferber joined aduro in  and currently serves as vice president associate general counsel prior to aduro she was with shearman  sterling llp where she served as counsel in the capital markets group  ms ferber has over  years of experience advising public and private companies on corporate and finance matters including securities offerings mergers acquisitions and strategic transactions corporate governance and securities law compliance before shearman  sterling ms ferber was counsel at morrison  foerster llp working in their palo alto hong kong and san diego offices ms ferber received her jd from the university of california hastings college of law and her ba in economics from bucknell university she is the author of numerous publications regarding legal matters nancy kaplan vice president human resources and facility operations nancy kaplan joined aduro in  and currently serves  as aduro’s vice president of human resources and facility operations prior to aduro ms kaplan worked with a wide variety of small biotech companies applying her broad generalist skill set to establish and bolster finance human resources facility management grant administration and investor relations functions in addition she was marketing communications manager at applied biosystems and supervised biotech accounts at lena chow advertising earlier in her career ms kaplan was part of the founding group at invitron corp a mammalian cell contract manufacturer ms kaplan holds a bs in agronomy from oregon state university anne moon phd vice president project management anne moon phd joined aduro in  and currently serves as vice president of project management prior to aduro dr moon was a founding team member of jennerex biotherapeutics acquired by sillajen where she served as vice president of product development earlier in her career dr moon was part of the startup team at cytokinetics establishing the cellbased screening program and served as project manager of the oncolytic virus program at onyx pharmaceuticals acquired by amgen after completing postdoctoral work within the small molecule therapeutics program targeting small gtpases she received her phd in molecular and cell biology from the university of california berkeley and her ba in biology from harvard university aimee murphy vice president clinical development and operations ms murphy joined aduro in  and currently serves as vice president of clinical development and operations  prior to aduro ms murphy advanced the development of the ladd live attenuated doubledeleted immunotherapy platform at both cerus corporation and anza therapeutics where she managed the first phase  studies that led to aduros existing ladd clinical programs prior to focusing on ladd she worked on the development of prophylactic vaccines and drugs for oncology and infectious diseases at vaxgen coulter pharmaceuticals and shaman pharmaceuticals additionally ms murphy brings experience in quality assurance from bayer pharmaceuticals she holds a bs in biology from pepperdine university justin skoble phd vice president technical operations justin skoble phd joined aduro in  and currently serves as aduro’s vice president of technical operations prior to aduro dr skoble held positions with increasing responsibilities in the molecular biology and process development departments at anza therapeutics and cerus corporation he earned his ba in biology from vassar college and his phd in molecular and cell biology from the university of california berkeley in the laboratory of dr daniel portnoy additionally dr skoble performed postdoctoral work at the university of california san francisco ucsf in the laboratory of dr jeff cox professor of microbiology and immunology at ucsf liana wu vice president commercial liana wu joined aduro in april  as vice president commercial bringing with her over  years of commercial experience in the biotechnology industry and a successful track record in brand development and product launches prior to aduro ms wu spent nine years at onyx pharmaceuticals acquired by amgen where she was most recently vice president oncology franchise while at onyx she was instrumental in overseeing the collaboration with bayer for nexavar and stivarga in the united states  earlier in her career ms wu held several sales and marketing positions at genentech with responsibilities associated with the company’s key oncology brands including rituxan herceptin and tarceva ms wu holds a master’s in public health from the johns hopkins university and a bs in economics from the wharton school at the university of pennsylvania leadership board of directors scientific advisory board culture global headquarters community affairs home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact privacy policy terms and conditions of use   aduro biotechall rights reserved privacy policy terms and conditions of use website design hane chow inc twitterlinkedin stephen t isaacs  center for global development skip to main content set homepage us international contribute social search center for global development ideas to action independent research for global prosperity enter your keywords donate  facebook  twitter  rss  youtube xsubscribe to cgd’s weekly newsletter below and watch for an email with the option to receive more of what interests you email address  first name  last name  organization  if not affiliated type individuals also sign me up to receive event invitations leave this field blank already subscribed please click “manage subscriptions” on any email from center for global development cgdemailcgdevorg to update your preferences privacy policy you are herehome stephen t isaacs tweet share print stephen t isaacs has served as aduro biotech’s chairman director president and chief executive officer since  aduro is a publicly traded clinical stage biotechnology company focused on immunooncology with additional programs in autoimmunity and infectious disease prior to aduro mr isaacs founded cerus corporation in  a biomedical products company commercializing the intercept blood systems the intercept systems are now globally available and used to prevent a variety of diseases from blood transfusion he served as president and chief executive officer of cerus from  to  prior to cerus mr isaacs founded and served as chief executive officer and president of hri associates and hri research both biotechnology companies focusing on research and development in various areas he held a nonteaching faculty position in the department of chemistry at the university of california berkeley from  to  mr isaacs has published over  peerreviewed scientific articles and is an inventor on over  issued patents  in addition to leading multiple biotechnology companies mr isaacs has spent considerable time on the african continent working on various nonprofit activities with his family he founded “a better education” abe club which provides educational opportunities microfinance training and healthcare for remote villagers in the south of kenya  more recently he founded the alliance for global health and science with the department of public health at uc berkeley which undertakes capacity building at universities and medical schools in uganda and zimbabwe  he also established the immunotherapeutics and  vaccine research initiative at uc berkeley which is an adurosponsored campuswide organization to promote immunological research for cancer and infectious disease   mr isaacs holds an undergraduate degree in biochemistry from the university of california at berkeley where he also pursued phd studies in organic chemistry isaacs stephen t  the wall street transcript stephen t isaacs stephen t isaacs is cofounder president and chief executive officer of cerus corporation under his direction cerus has established a leadership position in the biopharmaceutical industry prior to founding cerus in  mr isaacs was the cofounder president and chief executive officer of hri research inc prior to hri he held a faculty research position in the department of chemistry at the university of california at berkeley mr isaacs is a recognized international authority in the area of psoralen photochemistry a field in which he has authored numerous research papers and holds over  patents he is a member of the society for photochemistry and photobiology and the american association of blood banks mr isaacs serves on the board of directors of pan pacific pharmaceuticals inc and is a member of the scientific advisory board and board of regents at st mary’s college in moraga california mr isaacs earned a bachelor’s degree in biochemistry from the university of california at berkeley related interviewsstephen isaacs  cerus corporation cersoctober  stephen issacs  cerus corporation cersdecember 8 stephen t isaacs  cerus corporation cersjanuary   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july 8  in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google board of directors  aduro biotech pioneering immunotherapy transforming lives board of directors stephen t isaacs gerald chan dsc william m greenman ross haghighat frank mccormick phd frs dsc stephanie monaghan o’brien stephen a sherwin md stephen t isaacs   stephen t isaacs has served as our chairman president and chief executive officer since  prior to aduro in  mr isaacs founded cerus corporation a biomedical products company that commercialized the intercept blood systems he served as president and chief executive officer of cerus from  to  prior to cerus mr isaacs founded and served as chief executive officer and president of hri associates and hri research both biotechnology companies focusing on research and development he held a nonteaching faculty position in the department of chemistry at the university of california berkeley from  to  mr isaacs has published over  peerreviewed scientific articles and is an inventor on over  issued patents mr isaacs holds a ba degree in biochemistry from university of california berkeley and had graduate training in organic chemistry in the phd program in the department of chemistry at berkeley gerald chan dsc   dr gerald chan has served on our board of directors since  dr chan cofounded the morningside group a private investment group with venture private equity and property investments in  he has served as a member of the global advisory council of the international society for stem cell research since  the global advisory council of harvard university since  the dean’s board of advisors of the harvard school of public health since  the advisory boards of the cold spring harbor conferences asia since  the johns hopkins nanjing center since  and the columbia university center for radiological research since  dr chan also has been a member of the board of directors of hang lung group limited since  dr chan received his bs and ms degrees in engineering from the university of california los angeles and his master’s degree in medical radiological physics and doctor of science degree in radiation biology from harvard university he did his postdoctoral training at the danafarber cancer institute as a fellow of the leukemia society of america william m greenman   william m greenman has served as a member of our board of directors since  mr greenman is currently the president and chief executive officer of cerus corporation and has held several executive and management positions with cerus since joining the company in  prior to cerus he worked in various marketing and business development positions in baxter’s biotech division from  to  mr greenman holds undergraduate degrees in biological sciences and economics from stanford university  ross haghighat   ross haghighat has served as a member of our board of directors since  mr haghighat is the founder chairman and managing partner of triton systems inc  additionally mr haghighat has served on the board of directors of s technologies and frx polymers since  mr haghighat holds a bs and a masters in material science organometallic chemistry from rutgers university and a master of business administration from boston college  frank mccormick phd frs dsc   frank mccormick phd frs dsc hon has served as a member of our board of directors since  and is a member of the board’s science and technology committee since  dr mccormick has held the positions of director of the university of california san francisco ucsf helen diller family comprehensive cancer center a multidisciplinary research and clinical care organization as well as the position of associate dean of the ucsf school of medicine  additionally since  he has been a fellow of the royal society a society for science prior to joining the ucsf faculty dr mccormick pursued cancerrelated work with several biotechnology firms including cetus corporation as director of molecular biology from 8 to  and vice president of research from  to  and chiron corporation as vice president of research from  to  in  dr mccormick founded onyx pharmaceuticals acquired by amgen and served as the company’s chief scientific officer until  dr mccormick received his bsc in biochemistry from the university of birmingham and his phd in biochemistry from the university of cambridge and held postdoctoral fellowships in the united states at the state university of new york at stony brook and in london at the imperial cancer research fund  stephanie monaghan o’brien   stephanie monaghan o’brien has served as a member of our board of directors since  ms o’brien has been a member of the investment team at morningside since  she has served as a director for numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic focus including oncology and immunotherapy and has extensive experience providing operational and management oversight to venturebacked technology companies she has also facilitated multiple financings for public and private companies such as dendreon biovex stealth biotherapeutics and sohucom prior to joining morningside ms o’brien spent nine years as a corporate lawyer with hale and dorr in the boston and washington dc offices working primarily on public offerings venture capital finances and startup companies she previously worked at chase manhattan bank working in international portfolio analysis she received her ab cum laude from harvard college and her jd from new york university school of law  stephen a sherwin md   stephen a sherwin md has served on our board of directors since  and is a member of the board’s science and technology committee  dr sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology he is a clinical professor of medicine at the university of california san francisco and a volunteer attending physician in hematologyoncology at the zuckerberg san francisco general hospital in addition to his advisory work with aduro dr sherwin serves as a director of biogen neurocrine biosciences and rigel pharmaceuticals and as a venture partner at third rock ventures he is also a member of the scientific steering committee of the parker institute for cancer immunotherapy dr sherwin holds a ba in biology from yale university where he graduated summa cum laude and an md from harvard medical school he is boardcertified in internal medicine and medical oncology and a fellow of the american college of physicians leadership board of directors scientific advisory board culture global headquarters community affairs home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact privacy policy terms and conditions of use   aduro biotechall rights reserved privacy policy terms and conditions of use website design hane chow inc twitterlinkedin stephen t isaacs  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in stephen t isaacs chairman of the board president and chief executive officer at aduro biotech view full profile are you stephen t isaacs claim your profile   sign up for equilar atlas and view stephen t isaacss full profile with equilar atlas you can identify corporate executives in stephen t isaacss network and community follow changes in stephen t isaacss employment and moneyinmotion connect with stephen t isaacs through your network of contacts stephen t isaacss executive work history current chairman of the board president and chief executive officer aduro biotech past to view stephen t isaacss complete executive work history sign up now age      stephen t isaacss biography stephen t isaacs has served as our chairman of the board president and chief executive officer since  prior to aduro mr isaacs founded cerus corporation a biomedical products company commercializing the intercept blood systems in  he served as president and chief executive officer of cerus from  to  prior to cerus mr isaacs founded and served as chief executive officer and president of hris associates and hri research both biotechnology companies focusing on research and development he held a nonteaching faculty position in the department of chemistry at the university of california berkeley from  to  mr  read more stephen t isaacs has served as our chairman of the board president and chief executive officer since  prior to aduro mr isaacs founded cerus corporation a biomedical products company commercializing the intercept blood systems in  he served as president and chief executive officer of cerus from  to  prior to cerus mr isaacs founded and served as chief executive officer and president of hris associates and hri research both biotechnology companies focusing on research and development he held a nonteaching faculty position in the department of chemistry at the university of california berkeley from  to  mr isaacs has published over  peerreviewed scientific articles and is an inventor on over  issued patents mr isaacs holds a ba degree in biochemistry from university of california berkeley and had graduate training in organic chemistry in the phd program in the department of chemistry at berkeley because of mr isaacs biomedical expertise extensive knowledge of our company and experience as founder and executive officer of biotechnology companies we believe he is able to make valuable contributions to our board of directors source aduro biotech on    sign up for equilar atlas and view stephen t isaacss full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like stephen t isaacs more specifically youll be able to identify corporate executives in stephen t isaacss network and community follow changes in stephen t isaacss employment and moneyinmotion connect with stephen t isaacs through your network of conections view full profile   search for over  executive profiles bio example stephen t isaacs stephen t isaacss connections  sign up now to view stephen t isaacss  connections » frank mccormick former board member aduro biotech william r rohn former chief operating officer biogen inc stephanie m obrien former board member aduro biotech howard g ervin former vice president legal affairs cerus corporation william m greenman dir president and chief executive officer cerus corporation ross haghighat board member aduro biotech gregory w schafer chief operating officer aduro biotech charles r larkin board member align technology inc stephen a sherwin board member neurocrine biosciences inc john e hearst former vice president new science opportunities and director cerus corporation popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   insider trading  isaacs stephen t  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  isaacs stephen t select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm aduro biotech inc adro isaacs stephen tpresident and ceodirector   8 indirectdirect view sale  pm aduro biotech inc adro isaacs stephen tpresident and ceodirector  8  8indirectdirect view sale  pm aduro biotech inc adro isaacs stephen tpresident and ceodirector    indirectdirect view sale  pm aduro biotech inc adro isaacs stephen tpresident and ceodirector    8indirectdirect view sale  pm aduro biotech inc adro isaacs stephen tpresident and ceodirector    indirectdirect view sale  pm aduro biotech inc adro isaacs stephen tpresident and ceodirector    indirectdirect view sale 88 pm aduro biotech inc adro isaacs stephen tpresident and ceodirector   8 8indirectdirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view gift  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   indirect view option award  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   8direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   8direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   8direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   8direct view option award  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view option award 8 pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm na8 aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view option award  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise 88 pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   8direct view exercise 88 pm na aduro biotech inc adro isaacs stephen tpresident and ceodirector   8direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm  aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view exercise  pm  aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view conversion 8 pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view conversion 8 pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view conversion 8 pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view conversion 8 pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view conversion 8 pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view conversion 8 pm nana aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view disposition 8 pm  aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view option award 8 pm  aduro biotech inc adro isaacs stephen tpresident and ceodirector   direct view   secformcom all rights reserved archives        mon  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  oncologics inc appoints stephen t isaacs as president and chief executive officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km8  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       oncologics inc appoints stephen t isaacs as president and chief executive officer tweet   am berkeley califbusiness wireoncologic inc today announced that stephen isaacs has joined the company as president and ceo mr isaacs 8 is also a director of the company a position he has held for the past  months mr isaacs succeeds roy k skogstrom  who will become a consultant to the company and will remain as a director prior to joining oncologic mr isaacs founded cerus corporation nasdcers  news and then served over  years as its president and ceo cerus is a biotechnology company focused on the development of products for the decontamination of blood components and oncology applications during this period cerus grew from approximately  employees to over  while at cerus mr isaacs was responsible for running the company managing the companys growth and raising money to keep the project development programs on track he led the companys ipo in  and managed a number of secondary financings mr isaacs also drove numerous licensing and partnership deals including successfully negotiating agreements with baxter corporation intercept blood systems the consortium for plasma science kirin brewery cancer therapy and medimmune corporation cancer vaccines cerus now has two licensed products in europe under mr isaacs cerus raised approximately  million from public and private placements including contributions from various partnerships at oncologic mr isaacs will be responsible for daily management strategic planning fundraising and investor relations in addition he will coordinate technology and product development and strategic technology placement mr isaacs joins a very experienced scientific team lead by dr paul chinn chief scientific officer and dr gary braslawsky senior vicepresident and director of preclinical development both formerly of biogen idec nasdbiib  news where they were part of the senior scientific team responsible for the successful development and clinical approval of the anticancer drug zevalin® mr isaacs is a tremendous addition to the company said oncologic chairman winston salser phd founding president of amgen the worlds largest biotechnology company nasdamgn  news steves strong experience in managing growth public and private fundraising and commercializing a successful product give oncologic a management team capable of maximizing the potential of the companys opportunity salser continued outgoing president and ceo roy skogstrom will report to mr isaacs and will be in charge of special assignments as a consultant roy has led the company since its inception and has done an outstanding job we are thrilled to have both steve and roy as part of oncologic mr isaacs stated i look forward to working with my new colleagues and establishing collaborative partnerships to enable oncologic to achieve its full potential in both its core cancer technology and other strategic areas my  years at cerus will be valuable in guiding the company forward and im pleased to be working at a company cofounded by professor henry rapoport who was also a member of the founding team of cerus im looking forward to the challenge of making oncologic a successful biotechnology company mr isaacs holds a bachelors degree in biochemistry from uc berkeley and has authored  scientific publications and  us patents about oncologic inc oncologic inc is a privately held biotechnology company headquartered in berkeley california the company was founded by the late drs sam rose and henry rapoport to pioneer their highly innovative technology platform for the treatment of cancer contact oncologic inc david s rose 88 x cofounder  director of operations infooncologicnet source oncologic inc  discuss this story read at biospacecom related news oncologics inc release breast cancer treatment breakthrough astrazeneca plc azn jobs to trim 8 jobs in sweden part of broader cuts oncologics inc adds new system to treat cancer in lafayette bioheart inc appoints william h pinon president and ceo bayer ag bay jobs to cut  jobs worldwide oncologic appoints stephen t isaacs as president and chief executive officer abbott laboratories abt jobs says to pare back sales and research jobs pfizer japan inc to cut drug workforce by up to  percent bayer ag bay to slash  jobs in berlin vasogen vsgn appoints terry h gregg president  ceo please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • oncologics inc   • biotechpharma  personnel                 aduro biotech’s stephen t isaacs named  visionary leader by berkeley chamber of commerce nasdaqadro english français register sign in aduro biotech’s stephen t isaacs named  visionary leader by berkeley chamber of commerce september   8 et  source aduro biotech inc photorelease jpg stephen isaacs aduro biotech chairman president and ceo berkeley calif sept   globe newswire  aduro biotech inc nasdaqadro today announced that stephen t isaacs the company’s chairman president and ceo will receive the berkeley chamber of commerce visionary award one of three recipients for  mr isaacs was recognized for his commitment to innovation and his visionary leadership within the city of berkeley a photo accompanying this announcement is available at httpwwwglobenewswirecomnewsroomattachmentngabafb8b8e8fffb “steve is a consummate innovator and incredible leader” said g steven martin phd former dean of biological sciences at the university of california in berkeley “he is one of few in the industry with the foresight to begin advancing research in immunooncology over a decade ago additionally his visionary leadership has forged deep ties between biotech and academia as well as between the city of berkeley and countries around the world a prime example of this is aduro’s research collaboration with uc berkeley through their immunotherapeutics and vaccine research initiative ivri with the aim of accelerating breakthrough discoveries and making an impact on global health for his many accomplishments and admirable character i extend my sincerest congratulations to steve for this welldeserved award”     the berkeley chamber of commerce created the visionary awards to celebrate people with imagination and persistence to innovate in the city of berkeley long known as a city on the vanguard of public policy and social activism berkeley is growing its reputation as a place for worldleading companies these enterprises represent the latest generation of berkeleyans working to change the world their visions are key to the vitality of berkeley and the greater bay area with the unique attributes of uc berkeley the berkeley lab and the dynamic community entrepreneurs are choosing berkeley as the place to launch their ventures their companies are striving to meet the challenges of the next generation while at the same time creating jobs in the city the chamber has partnered with the city of berkeley the university of california and the lawrence berkeley national lab to showcase these leaders “we created the visionary awards to recognize people who are truly making a difference – for our local workforce for the community and especially in the case of steve and aduro for people suffering from devastating diseases” commented kirsten macdonald cochief executive officer of the berkeley chamber of commerce “we applaud steve for his persistence in approaching the challenging field of drug development with unique and innovative approaches for building a thriving biotechnology company and for identifying revolutionary ways to bring academia and industry together for the benefit of patients not only locally but also in the developing world” “it is a tremendous honor to be recognized by the chamber of commerce for innovation in this city which is known for its revolutionary thinking” said stephen t isaacs chairman president and chief executive officer of aduro “for over a decade we have been in berkeley working to bring new immunotherapies to patients to transform the treatment of cancer and other challenging diseases we look forward to our continued commitment to advance immunotherapy – for the benefit of patients employees and the community” about aduro aduro biotech inc is an immunotherapy company focused on the discovery development and commercialization of therapies that transform the treatment of challenging diseases aduros technology platforms which are designed to harness the bodys natural immune system are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases aduros ladd technology platform is based on proprietary attenuated strains of listeria that have been engineered to express tumorassociated antigens to induce specific and targeted immune responses this platform is being developed as a treatment for multiple indications including pancreatic ovarian lung and prostate cancers mesothelioma and glioblastoma aduros sting pathway activator platform is designed to activate the intracellular sting receptor resulting in a potent tumorspecific immune response adus is the first sting pathway activator compound to enter the clinic and is currently being evaluated in a phase  study in patients with cutaneously accessible metastatic solid tumors or lymphomas aduro’s bselect monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms for more information please visit wwwadurocom cautionary note on forwardlooking statements this press release contains forwardlooking statements for purposes of the safe harbor provisions of the private securities litigation reform act of  forwardlooking statements include statements regarding our intentions or current expectations concerning among other things the potential for our technology platforms plans and the potential for eventual regulatory approval of our product candidates in some cases you can identify these statements by forwardlooking words such as “may” “will” “continue” “anticipate” “intend” “could” “project” “expect” or the negative or plural of these words or similar expressions  forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated including but not limited to our history of net operating losses and uncertainty regarding our ability to achieve profitability our ability to develop and commercialize our product candidates our ability to use and expand our technology platforms to build a pipeline of product candidates our ability to obtain and maintain regulatory approval of our product candidates our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do our reliance on third parties and our ability to obtain and adequately protect intellectual property rights for our product candidates  we discuss many of these risks in greater detail under the heading “risk factors” contained in our quarterly report on form q for the quarter ended june   which is on file with the securities and exchange commission any forwardlooking statements that we make in this press release speak only as of the date of this press release we assume no obligation to update our forwardlooking statements whether as a result of new information future events or otherwise after the date of this press releasecontact sylvia wheeler svp corporate affairs  8  media contact angela bitting    pressadurocom related articles other press releases by aduro biotech inc aduro announces milestone achieved relating to collaboration with merck for development of anticd antibody for the treatment of cancer july   8 aduro biotech announces initiation of phase  clinical trial of crs in combination with keytruda® pembrolizumab for the treatment of previouslytreated gastroesophageal adenocarcinoma june    aduro biotech announces first patient dosed in phase  clinical trial of crs in combination with keytruda® pembrolizumab for the treatment of patients with previously treated malignant pleural mesothelioma june 8   aduro biotech announces fda clearance of investigational new drug application to evaluate the combination of adus with pdr for the treatment of solid tumors and lymphomas june   8 aduro biotech to host and webcast an investor event in conjunction with the  asco annual meeting may     other news releases in product  services announcement in the last  days profile aduro biotech inc   subscribe via rss  subscribe via atom  javascript berkeley california united states contact data contact sylvia wheeler svp corporate affairs  8  media contact angela bitting    pressadurocom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files jpg jpeg   x 8 image url  copy the link below stephen isaacs aduro biotech chairman president and ceo formats available original large medium small aduro biotech inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone 8  fax 8  european headquarters woolgate exchange  basinghall street london ecv ha uk phone  88   globenewswire inc all rights reserved stephen isaacs  cerus corporation  zoominfocom